Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 13Sarcoma 10Neoplasms 10Breast Neoplasms 8Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 3Colorectal Neoplasms 3Advanced Cancers 3Thyroid Neoplasms 2Solid Tumors 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lung Neoplasms 2Liver Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Wilms Tumor 1Unspecified Adult Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor - Protocol Specific 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumours 1Solid Neoplasm 1Recurrence 1Osteosarcoma 1Optic Nerve Glioma 1Neuroblastoma 1Lymphoma 1

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Neoplasm × pazopanib × Clear all
NCT01552356 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡